Pharmaceutical company Novartis, operating in 155 countries around the world, announced plans to merge with American Endocyte, the developer of targeted therapies for cancer treatment, finversia.ru writes. Novartis, according to the agreement, will pay $2 billion 100 million for an American company, acquiring all its ordinary shares at $24 per share, which is 1.5 times more than the price of one share at 5 dollars 56 cents at the closure of trading on Wednesday. The deal must also be approved by Endocyte shareholders and regulators.
Amazon to invest $100 Million in new warehouses located in Mexico19.10.2020
Alibaba Group Holdings to acquire Sun Art Retail Group in a deal worth $3.6 billion16.10.2020
Foxconn Technology Group wants to supply components to about 3 Million EVs in the next seven years16.10.2020
Fiat Chrysler invests $1.5 billion to produce electric vehicles in Canada